REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
04/21/2025
Back to search
Official data from USPTO
OP2 INNOVATIVE DRUGS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
42
Latest update
04/22/2025
Trademark type
Combined
Nice classes
1, 10
Filing date
03/13/2018
Registration date
04/21/2020
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
04/21/2020
Last transaction
04/22/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
34
Owner location
PESSAC CEDEX, FR
Examiner
EVANKO, PATTY
Law office
N10
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the stylized wording "OP2 INNOVATIVE DRUGS" with the letter "O" being an orange circle, the letter "P" in red, the number "2" in white on a purple circle, above the wording "INNOVATIVE DRUGS" in purple.
Holders and representatives
Holders
OP2 DRUGS
Representatives
Pina Campagna Carter, DeLuca, Farrell & Schmidt, LLP
Technical classification
Nice Classes
Class 1Class 10
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemicals for use in industry and science
Class 10
Medical apparatus and instruments for treating cardiovascular and neurological disease
Publications
History of USPTO decisions and trademark events.
42 publications found
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
09/26/2020
FICS
FINAL DISPOSITION NOTICE SENT TO IB
09/05/2020
FIMP
FINAL DISPOSITION PROCESSED
08/26/2020
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
07/21/2020
NREP
NEW REPRESENTATIVE AT IB RECEIVED
05/07/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
04/21/2020
ETOP
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
03/12/2020
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
12/06/2019
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
11/20/2019
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
11/20/2019
ETOF
EXTENSION OF TIME TO OPPOSE RECEIVED
09/30/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/03/2019
PUBO
PUBLISHED FOR OPPOSITION
09/03/2019
GPNX
NOTIFICATION PROCESSED BY IB
08/30/2019
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
08/14/2019
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
08/14/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08/14/2019
ALIE
ASSIGNED TO LIE
07/30/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/22/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/20/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/19/2019
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
07/19/2019
NREP
NEW REPRESENTATIVE AT IB RECEIVED
02/07/2019
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
01/21/2019
GNFR
FINAL REFUSAL E-MAILED
01/21/2019
CNFR
FINAL REFUSAL WRITTEN
01/21/2019
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
01/09/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/09/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/08/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/08/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/08/2019
NREP
NEW REPRESENTATIVE AT IB RECEIVED
01/04/2019
RFNT
REFUSAL PROCESSED BY IB
07/27/2018
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
07/09/2018
RFRR
REFUSAL PROCESSED BY MPU
07/09/2018
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
06/27/2018
CNRT
NON-FINAL ACTION WRITTEN
06/26/2018
DOCK
ASSIGNED TO EXAMINER
06/23/2018
MAFR
APPLICATION FILING RECEIPT MAILED
06/19/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/15/2018
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
06/14/2018
Continuous trademark protection
Get notified about every new filing that threatens OP2 INNOVATIVE DRUGS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.